Insights from immuno-oncology: The Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

Paolo Antonio Ascierto; Bernard Fox; Walter Urba; Ana Carrizosa Anderson; Michael B. Atkins; Ernest C. Borden; Julie Brahmer; Lisa H. Butterfield; Alessandra Cesano; Daniel Chen; Tanja De Gruijl; Robert O. Dillman; Charles G. Drake; Leisha A. Emens; Thomas F. Gajewski; James L. Gulley; F. Stephen Hodi; Patrick Hwu; David Kaufman; Howard Kaufman; Michael Lotze; Douglas G. McNeel; Kim Margolin; Francesco Marincola; Michael J. Mastrangelo; Marcela V. Maus; David R. Parkinson; Pedro J. Romero; Paul M. Sondel; Stefani Spranger; Mario Sznol; George J. Weiner; Jon M. Wiggington; Jeffrey S. Weber

doi:10.1136/jitc-2020-000878

Insights from immuno-oncology: The Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

Paolo Antonio Ascierto, Bernard Fox, Walter Urba, Ana Carrizosa Anderson, Michael B. Atkins, Ernest C. Borden, Julie Brahmer, Lisa H. Butterfield, Alessandra Cesano, Daniel Chen, Tanja De Gruijl, Robert O. Dillman, Charles G. Drake, Leisha A. Emens, Thomas F. Gajewski, James L. Gulley, F. Stephen Hodi, Patrick Hwu, David Kaufman, Howard KaufmanMichael Lotze, Douglas G. McNeel, Kim Margolin, Francesco Marincola, Michael J. Mastrangelo, Marcela V. Maus, David R. Parkinson, Pedro J. Romero, Paul M. Sondel, Stefani Spranger, Mario Sznol, George J. Weiner, Jon M. Wiggington, Jeffrey S. Weber

Melanoma Medical Oncology

Research output: Contribution to journal › Review article › peer-review

47 Scopus citations

Original language	English (US)
Article number	e000878
Journal	Journal for immunotherapy of cancer
Volume	8
Issue number	1
DOIs	https://doi.org/10.1136/jitc-2020-000878
State	Published - Apr 16 2020

Keywords

immunomodulation
inflammation mediators

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Molecular Medicine
Oncology
Pharmacology
Cancer Research

Access to Document

10.1136/jitc-2020-000878

Cite this

Ascierto, P. A., Fox, B., Urba, W., Anderson, A. C., Atkins, M. B., Borden, E. C., Brahmer, J., Butterfield, L. H., Cesano, A., Chen, D., De Gruijl, T., Dillman, R. O., Drake, C. G., Emens, L. A., Gajewski, T. F., Gulley, J. L., Stephen Hodi, F., Hwu, P., Kaufman, D., ... Weber, J. S. (2020). Insights from immuno-oncology: The Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. Journal for immunotherapy of cancer, 8(1), Article e000878. https://doi.org/10.1136/jitc-2020-000878

Ascierto, PA, Fox, B, Urba, W, Anderson, AC, Atkins, MB, Borden, EC, Brahmer, J, Butterfield, LH, Cesano, A, Chen, D, De Gruijl, T, Dillman, RO, Drake, CG, Emens, LA, Gajewski, TF, Gulley, JL, Stephen Hodi, F, Hwu, P, Kaufman, D, Kaufman, H, Lotze, M, McNeel, DG, Margolin, K, Marincola, F, Mastrangelo, MJ, Maus, MV, Parkinson, DR, Romero, PJ, Sondel, PM, Spranger, S, Sznol, M, Weiner, GJ, Wiggington, JM & Weber, JS 2020, 'Insights from immuno-oncology: The Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19', Journal for immunotherapy of cancer, vol. 8, no. 1, e000878. https://doi.org/10.1136/jitc-2020-000878

@article{7fb48689d6da4cd087eddb65bb6ffef2,

title = "Insights from immuno-oncology: The Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19",

keywords = "immunomodulation, inflammation mediators",

author = "Ascierto, {Paolo Antonio} and Bernard Fox and Walter Urba and Anderson, {Ana Carrizosa} and Atkins, {Michael B.} and Borden, {Ernest C.} and Julie Brahmer and Butterfield, {Lisa H.} and Alessandra Cesano and Daniel Chen and {De Gruijl}, Tanja and Dillman, {Robert O.} and Drake, {Charles G.} and Emens, {Leisha A.} and Gajewski, {Thomas F.} and Gulley, {James L.} and {Stephen Hodi}, F. and Patrick Hwu and David Kaufman and Howard Kaufman and Michael Lotze and McNeel, {Douglas G.} and Kim Margolin and Francesco Marincola and Mastrangelo, {Michael J.} and Maus, {Marcela V.} and Parkinson, {David R.} and Romero, {Pedro J.} and Sondel, {Paul M.} and Stefani Spranger and Mario Sznol and Weiner, {George J.} and Wiggington, {Jon M.} and Weber, {Jeffrey S.}",

note = "Funding Information: Competing interests PAA: Consultant/Advisory Role: Bristol-Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, NewLink Genetics, Genmab, Medimmune, AstraZeneca, Syndax, SunPharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar; Research Funds: Bristol-Myers Squibb, Roche-Genentech, Array; Travel support: MSD; BF: Cofounder/Stock: UbiVac; Consulting/Research Support: Macrogenics, OncoSec, Shimadzu, Viralytics (Merck); Consulting (II-ON)/Research Support: Bristol-Myers-Squibb; Consulting/Stock: PrimeVax; Research Support: NanoString, Quanterix; SAB: Argos, Bayer, CellDex, UltiVue; SAB/Institutional Research Support: AstraZeneca (MedImmunne); SAB/Research Support: Akoya BioScience (Perkin Elmer), Definiens; WJU: Advisory Board: MedImmune, Bristol-Myer Squibb; Research Support/Contracted Work: Bristol-Myers Squibb; Research Support: MedImmune; ACA: Consulting Fees: Tizona Therapeutics, Compass Therapeutics, Zumutor Biologics; Ownership Interest: VBI vaccines; Scientific Advisory Board: Compass Therapeutics, Zumutor Biologics Inc, Tizona Therapeutics; MBA: Advisory Board: Bristol-Myers Squibb, Merck, Novartis, Arrowhead, Pfizer, Galactone, Werewolf, Fathom; Consultant: Bristol-Myers Squibb, Novartis, Genetch-Roche, Exelixis, Eisai, Aveo, Array, AstraZeneca, Idera, Aduro, ImmunoCore, Boehringer-Ingelheim, Lion, Newlink, Surface, Alexion, Acceleron, Lynx, Cote; Research Support: Bristol-Myers Squibb; Stock Options: Werewolf; JB: Advisory Board: Amgen, BMS Celgene, Eli Lilly; Genentech, Merck, Syndax; Consulting: BMS, Genentech, Eli Lilly, Merck; Research/Grant Funding: MedImmune/AstraZeneca, Merck; LHB: Consulting Fees: StemImmune/Calidi Scientific and Medical Advisory Board, NextCure; Scientific Advisory Board: Replimmune, Western Oncolytics, Torque Therapeutics, Khloris, Pyxis, Cytomix, Roche-Genentech Biomarkers Roundtable; ACA: Consulting Fees: Refuge Bio, Arch Oncology, Qognit, Nanostring; Salary: ESSA Pharma; DC: Ownership Interest: IGM Biosciences; Salary: IGM Biosciences; CGD: Consultant Fees: Agenus, AstraZeneca, Dendreon, Eli Lilly, Janssen, Merck, Pierre Fabre, Roche/Genetech; Ownership Interests: Compugen, Harpoon, Kleo; Patents/Royalties: AstraZeneca, Bristol-Myers Squibb, Janssen; Research Funding: Aduro Biotech, Bristol-Myers Squibb, Janssen; LAE: Contracted Research: Aduro Biotech, AstraZeneca, Bristol-Myers Squibb, Corvus, EMD Serono, Genentech, F Hoffman La Roche, Maxcyte, Merck, Tempest; Consulting Fees: Genentech, F Hoffman La Roche, Syndax, Eli Lilly, AbbVie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Chugai, Genentech, F Hoffman La Roche, Gritstone, Medimmune, Macrogenics, Novartis, Peregrine, Replimune, Silverback, Vaccinex; IP Rights: Aduro Biotech; Royalty: Elsevier;Salary: University of Pittsburgh, UPMC UPP; Grants from non-industry entities: HeritX Incorporated, NSABP Foundation, Translational Breast Cancer Research Consortium, Breast Cancer Research Foundation, National Cancer Institute, Department of Defense, Johns Hopkins University, University of California San Francisco; TdG: Consulting Fees: DCPrime BV, Macrophage Pharma, Partner Therapeutics; Contracted Research: Idera Pharmaceuticals, Macrophage Parma; IP Rights/Patents: The use of cytostatics for the accelerated differentiation of DC WO2009019320-A2; WO2009019320-A3; AU2008285598-A1; EP2281030-A2; CA2724018-A1; US2011117051-A1. US8,470, 789B2 of DC prime BV, Immunoglobulins binding human V{\^I}³9V{\^I}'2 T cell receptors, CD1d domain antibodies targeting CD1d P32016NL00 EP16715360.0-1412, LAVA Tx BV; Ownership Interest: LAVA Therapeutics BV (stocks), Salary: Vrije Universiteit Medical Center Amsterdam; TFG: Consultant/Advisory Board: Roche-Genentech, Merck, Abbvie, Bayer, Jounce, Aduro, Fog Pharma, Adaptimmune, FivePrime, Sanofi; Research Support: Roche-Genentech, Bristol-Myers Squibb, Merck, Incyte, Seattle Genetics, Celldex, Ono, Evelo, Bayer, Adure; IP/Licensing: Aduro, Evelo; Cofounder/ shareholder: Jounce; FSH: Advisory Board: Aduro, Amgen, 7 Hills Pharma, Compass Therapeutics, Takeda, Rheos, Surface, Verastem; Advisory Board/Equity: Poinyr; Consulting Fees: Genetech/Roche, Bayer, Bristol-Myers Squibb, EMD Serono, Kairos, Merck, Partners Therapeutics, Sanofi, Pfizer, Pieris Pharmaceutical; Scientific Advisory Board/Equity: Apricity, Torque, Bicara; Grant/Royalties to Institution: Bristol-Myers Squibb, Novartis; PH: Consulting Fees: Immatics, Sanofi, Dragonfly, GlaxoSmithKline; DK: Scientific Advisory Board, Celsius Therapeutics, Hookipa Pharma; HK: Salary: Immuneering Corporation; ML: Consulting Fees: Torque, Repertone, Checkmate, Salary: Iovance; FM: Consulting Fees: Calidi Biotechnologies, Salary: Refuge Biotechnologies; KM: Consulting Fees: ImaginAb SAB, Iovance DMC, Neoleukin ad board (Non CME Services, <10k/year from each entity); MVM: Consulting/Advising: Adaptimmune Therapeutics, Agentus, Agenus inc, Allogene, Arcellx, Bluebird Bio, GSK, Incysus, Kite Pharma, Novartis; Scientific Advisory Boards: Century Therapeutics, CRISPR Therapeutics. TCR2, WindMIL Therapeutics; DGM: Clinical Trial Contracts (Served as PI): Merck, Bristol-Myers Squibb, Janssen, Pfizer, Novartis; Consulting Fees: Madison Vaccines; Contracted Research: Madison Vaccines, Merck; Ownership Interest: Madison Vaccines; DRP: President & CEO: ESSA Pharma; Board of Directors: CTI BioPharma, Tocagen, 3SBio; Scientific Advisory Board: Caris Life Science; PJR: Scientific advisory board: Immatics Biotechnologies, NexImmune, Life Science Partners, Speaker Fees: Bristol-Myers Squibb, Roche Pars, Astra Zeneca; SS: Consulting Fees: Arcus, Dragonfly, Merck, Ribon, Replimune, Takeda, Tango; Partner Salary: Nanoview",

year = "2020",

month = apr,

day = "16",

doi = "10.1136/jitc-2020-000878",

language = "English (US)",

volume = "8",

journal = "Journal for immunotherapy of cancer",

issn = "2051-1426",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Insights from immuno-oncology

T2 - The Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

AU - Ascierto, Paolo Antonio

AU - Fox, Bernard

AU - Urba, Walter

AU - Anderson, Ana Carrizosa

AU - Atkins, Michael B.

AU - Borden, Ernest C.

AU - Brahmer, Julie

AU - Butterfield, Lisa H.

AU - Cesano, Alessandra

AU - Chen, Daniel

AU - De Gruijl, Tanja

AU - Dillman, Robert O.

AU - Drake, Charles G.

AU - Emens, Leisha A.

AU - Gajewski, Thomas F.

AU - Gulley, James L.

AU - Stephen Hodi, F.

AU - Hwu, Patrick

AU - Kaufman, David

AU - Kaufman, Howard

AU - Lotze, Michael

AU - McNeel, Douglas G.

AU - Margolin, Kim

AU - Marincola, Francesco

AU - Mastrangelo, Michael J.

AU - Maus, Marcela V.

AU - Parkinson, David R.

AU - Romero, Pedro J.

AU - Sondel, Paul M.

AU - Spranger, Stefani

AU - Sznol, Mario

AU - Weiner, George J.

AU - Wiggington, Jon M.

AU - Weber, Jeffrey S.

N1 - Funding Information: Competing interests PAA: Consultant/Advisory Role: Bristol-Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, NewLink Genetics, Genmab, Medimmune, AstraZeneca, Syndax, SunPharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar; Research Funds: Bristol-Myers Squibb, Roche-Genentech, Array; Travel support: MSD; BF: Cofounder/Stock: UbiVac; Consulting/Research Support: Macrogenics, OncoSec, Shimadzu, Viralytics (Merck); Consulting (II-ON)/Research Support: Bristol-Myers-Squibb; Consulting/Stock: PrimeVax; Research Support: NanoString, Quanterix; SAB: Argos, Bayer, CellDex, UltiVue; SAB/Institutional Research Support: AstraZeneca (MedImmunne); SAB/Research Support: Akoya BioScience (Perkin Elmer), Definiens; WJU: Advisory Board: MedImmune, Bristol-Myer Squibb; Research Support/Contracted Work: Bristol-Myers Squibb; Research Support: MedImmune; ACA: Consulting Fees: Tizona Therapeutics, Compass Therapeutics, Zumutor Biologics; Ownership Interest: VBI vaccines; Scientific Advisory Board: Compass Therapeutics, Zumutor Biologics Inc, Tizona Therapeutics; MBA: Advisory Board: Bristol-Myers Squibb, Merck, Novartis, Arrowhead, Pfizer, Galactone, Werewolf, Fathom; Consultant: Bristol-Myers Squibb, Novartis, Genetch-Roche, Exelixis, Eisai, Aveo, Array, AstraZeneca, Idera, Aduro, ImmunoCore, Boehringer-Ingelheim, Lion, Newlink, Surface, Alexion, Acceleron, Lynx, Cote; Research Support: Bristol-Myers Squibb; Stock Options: Werewolf; JB: Advisory Board: Amgen, BMS Celgene, Eli Lilly; Genentech, Merck, Syndax; Consulting: BMS, Genentech, Eli Lilly, Merck; Research/Grant Funding: MedImmune/AstraZeneca, Merck; LHB: Consulting Fees: StemImmune/Calidi Scientific and Medical Advisory Board, NextCure; Scientific Advisory Board: Replimmune, Western Oncolytics, Torque Therapeutics, Khloris, Pyxis, Cytomix, Roche-Genentech Biomarkers Roundtable; ACA: Consulting Fees: Refuge Bio, Arch Oncology, Qognit, Nanostring; Salary: ESSA Pharma; DC: Ownership Interest: IGM Biosciences; Salary: IGM Biosciences; CGD: Consultant Fees: Agenus, AstraZeneca, Dendreon, Eli Lilly, Janssen, Merck, Pierre Fabre, Roche/Genetech; Ownership Interests: Compugen, Harpoon, Kleo; Patents/Royalties: AstraZeneca, Bristol-Myers Squibb, Janssen; Research Funding: Aduro Biotech, Bristol-Myers Squibb, Janssen; LAE: Contracted Research: Aduro Biotech, AstraZeneca, Bristol-Myers Squibb, Corvus, EMD Serono, Genentech, F Hoffman La Roche, Maxcyte, Merck, Tempest; Consulting Fees: Genentech, F Hoffman La Roche, Syndax, Eli Lilly, AbbVie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Chugai, Genentech, F Hoffman La Roche, Gritstone, Medimmune, Macrogenics, Novartis, Peregrine, Replimune, Silverback, Vaccinex; IP Rights: Aduro Biotech; Royalty: Elsevier;Salary: University of Pittsburgh, UPMC UPP; Grants from non-industry entities: HeritX Incorporated, NSABP Foundation, Translational Breast Cancer Research Consortium, Breast Cancer Research Foundation, National Cancer Institute, Department of Defense, Johns Hopkins University, University of California San Francisco; TdG: Consulting Fees: DCPrime BV, Macrophage Pharma, Partner Therapeutics; Contracted Research: Idera Pharmaceuticals, Macrophage Parma; IP Rights/Patents: The use of cytostatics for the accelerated differentiation of DC WO2009019320-A2; WO2009019320-A3; AU2008285598-A1; EP2281030-A2; CA2724018-A1; US2011117051-A1. US8,470, 789B2 of DC prime BV, Immunoglobulins binding human VÎ³9VÎ'2 T cell receptors, CD1d domain antibodies targeting CD1d P32016NL00 EP16715360.0-1412, LAVA Tx BV; Ownership Interest: LAVA Therapeutics BV (stocks), Salary: Vrije Universiteit Medical Center Amsterdam; TFG: Consultant/Advisory Board: Roche-Genentech, Merck, Abbvie, Bayer, Jounce, Aduro, Fog Pharma, Adaptimmune, FivePrime, Sanofi; Research Support: Roche-Genentech, Bristol-Myers Squibb, Merck, Incyte, Seattle Genetics, Celldex, Ono, Evelo, Bayer, Adure; IP/Licensing: Aduro, Evelo; Cofounder/ shareholder: Jounce; FSH: Advisory Board: Aduro, Amgen, 7 Hills Pharma, Compass Therapeutics, Takeda, Rheos, Surface, Verastem; Advisory Board/Equity: Poinyr; Consulting Fees: Genetech/Roche, Bayer, Bristol-Myers Squibb, EMD Serono, Kairos, Merck, Partners Therapeutics, Sanofi, Pfizer, Pieris Pharmaceutical; Scientific Advisory Board/Equity: Apricity, Torque, Bicara; Grant/Royalties to Institution: Bristol-Myers Squibb, Novartis; PH: Consulting Fees: Immatics, Sanofi, Dragonfly, GlaxoSmithKline; DK: Scientific Advisory Board, Celsius Therapeutics, Hookipa Pharma; HK: Salary: Immuneering Corporation; ML: Consulting Fees: Torque, Repertone, Checkmate, Salary: Iovance; FM: Consulting Fees: Calidi Biotechnologies, Salary: Refuge Biotechnologies; KM: Consulting Fees: ImaginAb SAB, Iovance DMC, Neoleukin ad board (Non CME Services, <10k/year from each entity); MVM: Consulting/Advising: Adaptimmune Therapeutics, Agentus, Agenus inc, Allogene, Arcellx, Bluebird Bio, GSK, Incysus, Kite Pharma, Novartis; Scientific Advisory Boards: Century Therapeutics, CRISPR Therapeutics. TCR2, WindMIL Therapeutics; DGM: Clinical Trial Contracts (Served as PI): Merck, Bristol-Myers Squibb, Janssen, Pfizer, Novartis; Consulting Fees: Madison Vaccines; Contracted Research: Madison Vaccines, Merck; Ownership Interest: Madison Vaccines; DRP: President & CEO: ESSA Pharma; Board of Directors: CTI BioPharma, Tocagen, 3SBio; Scientific Advisory Board: Caris Life Science; PJR: Scientific advisory board: Immatics Biotechnologies, NexImmune, Life Science Partners, Speaker Fees: Bristol-Myers Squibb, Roche Pars, Astra Zeneca; SS: Consulting Fees: Arcus, Dragonfly, Merck, Ribon, Replimune, Takeda, Tango; Partner Salary: Nanoview

PY - 2020/4/16

Y1 - 2020/4/16

KW - immunomodulation

KW - inflammation mediators

UR - http://www.scopus.com/inward/record.url?scp=85083631808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85083631808&partnerID=8YFLogxK

U2 - 10.1136/jitc-2020-000878

DO - 10.1136/jitc-2020-000878

M3 - Review article

C2 - 32300051

AN - SCOPUS:85083631808

SN - 2051-1426

VL - 8

JO - Journal for immunotherapy of cancer

JF - Journal for immunotherapy of cancer

IS - 1

M1 - e000878

ER -

Insights from immuno-oncology: The Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this